Combination of a p53-activating CP-31398 and an MDM2 or a FAK inhibitor produces growth suppressive effects in mesothelioma with wild-type p53 genotype.
Saved in:
| Title: | Combination of a p53-activating CP-31398 and an MDM2 or a FAK inhibitor produces growth suppressive effects in mesothelioma with wild-type p53 genotype. |
|---|---|
| Authors: | Zhong B; Division of Pathology and Cell Therapy, Chiba Cancer Center Research Institute, 666-2 Nitona, Chuo-ku, Chiba, 260-8717, Japan.; Department of Molecular Biology and Oncology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba, Japan., Shingyoji M; Division of Respirology, Chiba Cancer Center, 666-2 Nitona, Chuo-ku, 260-8717, Chiba, Japan., Hanazono M; Division of Pathology and Cell Therapy, Chiba Cancer Center Research Institute, 666-2 Nitona, Chuo-ku, Chiba, 260-8717, Japan., Nguyễn TT; Division of Pathology and Cell Therapy, Chiba Cancer Center Research Institute, 666-2 Nitona, Chuo-ku, Chiba, 260-8717, Japan.; Department of Molecular Biology and Oncology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba, Japan., Morinaga T; Division of Pathology and Cell Therapy, Chiba Cancer Center Research Institute, 666-2 Nitona, Chuo-ku, Chiba, 260-8717, Japan., Tada Y; Department of Pulmonary Medicine, International University of Health and Welfare, 852 Hatakeda, 286-8520, Narita, Japan., Shimada H; Department of Surgery, Graduate School of Medicine, Toho University, 6-11-1 Oomori-nishi, Oota-ku, 143-8541, Tokyo, Japan., Hiroshima K; Department of Pathology, Tokyo Women's Medical University Yachiyo Medical Center, 477-96, Ohwadashinden, Yachiyo, Chiba, 276-8524, Japan.; Department of Biochemistry and Genetics, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8717, Japan., Tagawa M; Division of Pathology and Cell Therapy, Chiba Cancer Center Research Institute, 666-2 Nitona, Chuo-ku, Chiba, 260-8717, Japan. mtagawa@chiba-cc.jp.; Department of Molecular Biology and Oncology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba, Japan. mtagawa@chiba-cc.jp.; Department of Biochemistry and Genetics, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8717, Japan. mtagawa@chiba-cc.jp.; Funabashi Orthopaedic Hospital, 1-833 Hazama, Funabashi, 274-0822, Japan. mtagawa@chiba-cc.jp. |
| Source: | Apoptosis : an international journal on programmed cell death [Apoptosis] 2020 Aug; Vol. 25 (7-8), pp. 535-547. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Springer Country of Publication: Netherlands NLM ID: 9712129 Publication Model: Print Cited Medium: Internet ISSN: 1573-675X (Electronic) Linking ISSN: 13608185 NLM ISO Abbreviation: Apoptosis Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 32468177 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Combination of a p53-activating CP-31398 and an MDM2 or a FAK inhibitor produces growth suppressive effects in mesothelioma with wild-type p53 genotype. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Zhong+B%22">Zhong B</searchLink>; Division of Pathology and Cell Therapy, Chiba Cancer Center Research Institute, 666-2 Nitona, Chuo-ku, Chiba, 260-8717, Japan.; Department of Molecular Biology and Oncology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba, Japan.<br /><searchLink fieldCode="AU" term="%22Shingyoji+M%22">Shingyoji M</searchLink>; Division of Respirology, Chiba Cancer Center, 666-2 Nitona, Chuo-ku, 260-8717, Chiba, Japan.<br /><searchLink fieldCode="AU" term="%22Hanazono+M%22">Hanazono M</searchLink>; Division of Pathology and Cell Therapy, Chiba Cancer Center Research Institute, 666-2 Nitona, Chuo-ku, Chiba, 260-8717, Japan.<br /><searchLink fieldCode="AU" term="%22Nguyễn+TT%22">Nguyễn TT</searchLink>; Division of Pathology and Cell Therapy, Chiba Cancer Center Research Institute, 666-2 Nitona, Chuo-ku, Chiba, 260-8717, Japan.; Department of Molecular Biology and Oncology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba, Japan.<br /><searchLink fieldCode="AU" term="%22Morinaga+T%22">Morinaga T</searchLink>; Division of Pathology and Cell Therapy, Chiba Cancer Center Research Institute, 666-2 Nitona, Chuo-ku, Chiba, 260-8717, Japan.<br /><searchLink fieldCode="AU" term="%22Tada+Y%22">Tada Y</searchLink>; Department of Pulmonary Medicine, International University of Health and Welfare, 852 Hatakeda, 286-8520, Narita, Japan.<br /><searchLink fieldCode="AU" term="%22Shimada+H%22">Shimada H</searchLink>; Department of Surgery, Graduate School of Medicine, Toho University, 6-11-1 Oomori-nishi, Oota-ku, 143-8541, Tokyo, Japan.<br /><searchLink fieldCode="AU" term="%22Hiroshima+K%22">Hiroshima K</searchLink>; Department of Pathology, Tokyo Women's Medical University Yachiyo Medical Center, 477-96, Ohwadashinden, Yachiyo, Chiba, 276-8524, Japan.; Department of Biochemistry and Genetics, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8717, Japan.<br /><searchLink fieldCode="AU" term="%22Tagawa+M%22">Tagawa M</searchLink>; Division of Pathology and Cell Therapy, Chiba Cancer Center Research Institute, 666-2 Nitona, Chuo-ku, Chiba, 260-8717, Japan. mtagawa@chiba-cc.jp.; Department of Molecular Biology and Oncology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba, Japan. mtagawa@chiba-cc.jp.; Department of Biochemistry and Genetics, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8717, Japan. mtagawa@chiba-cc.jp.; Funabashi Orthopaedic Hospital, 1-833 Hazama, Funabashi, 274-0822, Japan. mtagawa@chiba-cc.jp. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%229712129%22">Apoptosis : an international journal on programmed cell death</searchLink> [Apoptosis] 2020 Aug; Vol. 25 (7-8), pp. 535-547. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer%22">Springer </searchLink><i>Country of Publication: </i>Netherlands <i>NLM ID: </i>9712129 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1573-675X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2213608185%22">13608185 </searchLink><i>NLM ISO Abbreviation: </i>Apoptosis <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=32468177 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1007/s10495-020-01612-6 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 535 Titles: – TitleFull: Combination of a p53-activating CP-31398 and an MDM2 or a FAK inhibitor produces growth suppressive effects in mesothelioma with wild-type p53 genotype. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Zhong B – PersonEntity: Name: NameFull: Shingyoji M – PersonEntity: Name: NameFull: Hanazono M – PersonEntity: Name: NameFull: Nguyễn TT – PersonEntity: Name: NameFull: Morinaga T – PersonEntity: Name: NameFull: Tada Y – PersonEntity: Name: NameFull: Shimada H – PersonEntity: Name: NameFull: Hiroshima K – PersonEntity: Name: NameFull: Tagawa M IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 08 Text: 2020 Aug Type: published Y: 2020 Identifiers: – Type: issn-electronic Value: 1573-675X Numbering: – Type: volume Value: 25 – Type: issue Value: 7-8 Titles: – TitleFull: Apoptosis : an international journal on programmed cell death Type: main |
| ResultId | 1 |
